Such downregulation of PXR, CYP3A11 and GSTa2 and upregulation of drug transporters is expected to have important implications in the treatment regimen of hepatic cancer that could potentially dysregulate hepatic drug biotransformation and bioavailability of administered drugs. This evidence concerns the gene GSTA2 and liver cancer.